Evidence map›Paper›PMID 39394129›Full record

ArticleOrphanet journal of rare diseases2024

Pain in recessive dystrophic epidermolysis bullosa (RDEB): findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES).

Eunice Jeffs, Elizabeth I Pillay, Lesedi Ledwaba-Chapman, Alessandra Bisquera, Susan J Robertson, John A McGrath, Yanzhong Wang, Anna E Martinez, Jemima E Mellerio

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eunice JeffsSt. John's Institute of Dermatology , Guy's and St Thomas' NHS Foundation Trust, London, UK. eunice.jeffs@nhs.net.ORCID 0000-0001-6695-354X
Elizabeth I PillaySt. John's Institute of Dermatology , Guy's and St Thomas' NHS Foundation Trust, London, UK.
Lesedi Ledwaba-ChapmanDepartment of Population Health Sciences, King's College London, London, UK.
Alessandra BisqueraDepartment of Population Health Sciences, King's College London, London, UK.
Susan J RobertsonDepartments of Dermatology, The Royal Children's Hospital, The Royal Melbourne Hospital and Murdoch Children's Research Institute, Melbourne, Australia.
John A McGrathGenetic Skin Disease Group, King's College London, London, UK.
Yanzhong WangDepartment of Population Health Sciences, King's College London, London, UK.
Anna E MartinezDepartment of Dermatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Jemima E MellerioSt. John's Institute of Dermatology , Guy's and St Thomas' NHS Foundation Trust, London, UK.

Funding

Dystrophic Epidermolysis Bullosa Research Association Mellerio01
6 · The paper itself

Abstract

backgroundPain is common in the genetic skin fragility disorder epidermolysis bullosa (EB), from skin and mucosal injury and inflammation as well as extra-mucocutaneous sites. Individuals living with EB have identified pain as a priority for better treatments.

objectivesThe Prospective EB Longitudinal Evaluation Study (PEBLES) is a prospective register study exploring the natural history of RDEB across all ages from birth to death. Here, we investigated the characteristics and treatment of pain in different RDEB subtypes.

methodsInformation was collected from individuals with different RDEB subtypes over an 8-year period. Data included visual analogue scale (VAS) ratings of background and procedural pain, its location, intensity and impact on sleep, as well as pain medication. Disease severity scores and quality of life measures were correlated to pain scores.

resultsSixty-one participants (13 children, 48 adults) completed a total of 361 reviews. Pain was common, experienced by 93% of participants at index review, with 80% suffering both background and procedural pain. Across all RDEB patients, the median VAS for background pain was 40 (out of 100) [interquartile range 20,60] and for those having regular dressing changes, median procedural pain was 52 [40,80]. Severe (RDEB-S) and pruriginosa (RDEB-Pru) groups had the greatest increase in procedural compared to background pain of 20 and 22 VAS points, respectively. Correlations between disease severity and quality of life impairment were observed across most groups, particularly RDEB-S. Over half of those studied experienced pain frequently or constantly, and in one third pain disturbed sleep at least 4 nights per week. Skin was the commonest source of pain in all subtypes except inversa RDEB where the mouth was the main site. Despite frequent and severe pain, one third of participants used no medication for pain and, in those that did, pain levels remained high suggesting ineffectiveness of current pain management approaches and a significant unmet need in RDEB.

conclusionThe frequency, severity, and impact of pain in all RDEB patients is significant, particularly in RDEB-S and RDEB-Pru. Our findings highlight that current RDEB pain management is poorly effective and that further research is needed to address this symptom.

Indexed as

Epidermolysis Bullosa DystrophicaPainQuality of LifeAdolescentAdultChildChild, PreschoolFemaleHumansInfantLongitudinal StudiesMaleMiddle AgedPain MeasurementProspective StudiesYoung AdultDisease severityEpidermolysis bullosaNatural historyPainQuality of life

Identifiers

PMID39394129
PMCPMC11468479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.